A CIRCULATING NON-CODING RNA AS PREDICTOR OF MORTALITY IN PATIENTS WITH ACUTE KIDNEY INJURY

Number of patents in Portfolio can not be more than 2000

United States of America Patent

APP PUB NO 20170240969A1
SERIAL NO

15503612

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to a a method for predicting mortality of a test patient with acute kidney injury comprising (a) detecting the expression level of the non-coding RNA (ncRNA) of SEQ ID NO: 1 in a sample obtained from said test patient with acute kidney injury, (b) comparing said expression level of the ncRNA with the expression level of this ncRNA in a sample obtained from control patients with acute kidney injury or with a predetermined standard expression level of this ncRNA which was obtained on the basis of a sample from control patients with acute kidney injury, wherein the control patients were alive at least about 4 weeks after diagnosis of the acute kidney injury, and a greater than 1.5-fold overexpression of the ncRNA in the test patient's sample as compared to the control patient's sample or as compared to the predetermined standard is indicative of an enhanced likelihood for future death of the test patient due to renal failure; and/or (b′) comparing said expression level of the ncRNA with the expression level of this ncRNA in a sample obtained from control patients with acute kidney injury or with a predetermined standard expression level of this ncRNA which was obtained on the basis of a sample from control patients with acute kidney injury, wherein the control patients died from renal failure within about 4 weeks after diagnosis of acute kidney injury, and a greater than 1.5-fold underexpression of at the ncRNA in the test patient's sample as compared to the control patient's sample or as compared to the predetermined standard is indicative of an enhanced likelihood for the long term survival of the test patient; and/or (b″) comparing said expression level of the ncRNA with the expression level of the ncRNA in a sample obtained from a healthy subject or with a predetermined standard expression level of this ncRNA which was obtained on the basis of at least one sample from a healthy subject, wherein a greater than 5-fold overexpression of the ncRNA in the test patient's sample as compared to the healthy sample or as compared to the predetermined standard is indicative of an enhanced likelihood for future death of the test patient due to renal failure.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
MEDIZINISCHE HOCHSCHULE HANNOVERCARL-NEUBERG-STRASSE 1 HANNOVER 30625

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
LORENZEN, Johan Hannover, DE 2 0
THUM, Thomas Hannover, DE 34 116

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation